drugset / Trial / NCT00447837

Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis

NCT00447837

Phase 2 Completed 180 enrolled Naryx Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of the study is to evaluate the safety and efficacy of SPRC-AB01 versus placebo for treatment of chronic sinusitis in subjects who have had sinus surgery.

Timeline

Start
2006-10
Primary completion
2007-12
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 90 mg Inhaled
Subject Tobramycin Small molecule 180 mg Inhaled